HCT approaches and demographic shifts that might lower cGVHD-IS rates. Proportions shown by the 5-year eras in HCT date (A) and nonmutually exclusive GVHD prophylaxis categories (B). ATG, antithymocyte globulin; CNI, calcineurin inhibitor; CY, cyclophosphamide; MMF, mycophenolate mofetil; PTCY, posttransplant cyclophosphamide; TCD, T-cell depletion.